Editas Medicine, Inc.
(NASDAQ:EDIT)
$9.67
0.12 (1.26%)
At Close: 4:00 PM
$9.77
0.10 (1.03%)
After Market: 3:41 AM
EDIT Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
EDIT Stock Price Today
Editas Medicine, Inc. (EDIT) stock rallied over 1.26% intraday to trade at $9.67 a share on NASDAQ. The stock opened with a gain of 1.47% at $9.69 and touched an intraday high of $9.93, rising 1.26% against the last close of $9.55. The Editas Medicine, Inc. in stock market went to a low of $9.43 during the session.
EDIT Stock Snapshot
$9.55
Prev. Close
689.19 Million
Market Cap
$9.43
Day Low
$9.69
Open
68.92 Million
Number of Shares
$9.93
Day High
N/A
P/E ratio
-3.18
EPS (TTM)
4.75
Cash Flow per Share
27.56
Free Float in %
4.74
Book Value
1280166.00
Volume
EDIT Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2023-02-14 | $9.92 | $10.25 | $9.65 | $10.13 | 987579.00 |
| 2023-02-13 | $9.75 | $10.08 | $9.52 | $9.99 | 1102200.00 |
| 2023-02-10 | $9.91 | $9.95 | $9.61 | $9.76 | 1678300.00 |
| 2023-02-08 | $11.16 | $11.25 | $10.33 | $10.34 | 1597153.00 |
| 2023-02-07 | $11.10 | $11.32 | $10.82 | $11.22 | 1778300.00 |
| 2023-02-06 | $11.15 | $11.48 | $11.01 | $11.12 | 1625300.00 |
| 2023-02-03 | $11.09 | $11.93 | $10.99 | $11.26 | 2553732.00 |
| 2023-02-02 | $10.82 | $11.88 | $10.80 | $11.53 | 3522800.00 |
| 2023-02-01 | $10.30 | $10.62 | $9.78 | $10.41 | 2436200.00 |
| 2023-01-31 | $9.48 | $10.32 | $9.46 | $9.89 | 2463100.00 |
Contact Details
Company Information
Employees226.00
Beta1.82
Sales or Revenue$22.79 Million
5Y Sales Change7.50%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Frequently Asked Questions
What is the current Editas Medicine, Inc. (EDIT) stock price?
Editas Medicine, Inc. (NASDAQ: EDIT) stock price is $9.67 in the last trading session. During the trading session, EDIT stock reached the peak price of $9.93 while $9.43 was the lowest point it dropped to. The percentage change in EDIT stock occurred in the recent session was 1.26% while the dollar amount for the price change in EDIT stock was $0.12.
EDIT's industry and sector of operation?
The NASDAQ listed EDIT is part of Biotechnology industry that operates in the broader Healthcare sector. Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
Who are the executives of EDIT?
Ms. Michelle Robertson
Chief Financial Officer, Principal Accounting Officer, Treasurer & Assistant Sec.
Mr. Harry R. Gill III
Senior Vice President of Operations
Mr. James C. Mullen
Executive Chairman
Dr. Bruce E. Eaton Ph.D.
Executive Vice President & Chief Bus. Officer
How EDIT did perform over past 52-week?
EDIT's closing price is 0.38% higher than its 52-week low of $6.33 where as its distance from 52-week high of $19.97 is -0.56%.
How many employees does EDIT have?
Number of EDIT employees currently stands at 226.00. EDIT operates from 11 Hurley Street</br>Cambridge, MA 02141</br>US.
Link for EDIT official website?
Official Website of EDIT is: https://www.editasmedicine.com
How do I contact EDIT?
EDIT could be contacted at phone #617 401 9000 and can also be accessed through its website. EDIT operates from 11 Hurley Street</br>Cambridge, MA 02141</br>US.
How many shares of EDIT are traded daily?
EDIT stock volume for the day was 1280166.00 shares. The average number of EDIT shares traded daily for last 3 months was 1.84 Million.
What is the market cap of EDIT currently?
The market value of EDIT currently stands at $689.19 Million with its latest stock price at $9.67 and 68.92 Million of its shares outstanding.